Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.740
-0.060 (-3.33%)
At close: Jan 23, 2026, 4:00 PM EST
1.740
0.00 (0.00%)
After-hours: Jan 23, 2026, 5:15 PM EST
Inhibikase Therapeutics Employees
As of December 31, 2024, Inhibikase Therapeutics had 16 total employees, including 15 full-time and 1 part-time employees. The number of employees increased by 7 or 77.78% compared to the previous year.
Employees
16
Change (1Y)
7
Growth (1Y)
77.78%
Revenue / Employee
n/a
Profits / Employee
-$2,978,570
Market Cap
238.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 16 | 7 | 77.78% | 15 | 1 |
| Dec 31, 2023 | 9 | 2 | 28.57% | 8 | 1 |
| Dec 31, 2022 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2021 | 7 | 4 | 133.33% | 6 | 1 |
| Dec 31, 2020 | 3 | 1 | 50.00% | 3 | 0 |
| Sep 30, 2020 | 2 | - | - | 2 | 0 |
| Jun 30, 2020 | 2 | - | - | 2 | 0 |
| Mar 31, 2020 | 2 | - | - | 2 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Voyager Therapeutics | 172 |
| Coherus Oncology | 158 |
| MediWound | 111 |
| Tonix Pharmaceuticals Holding | 81 |
| Enlivex Therapeutics | 71 |
| Orchestra BioMed Holdings | 70 |
| Ovid Therapeutics | 23 |
| Climb Bio | 18 |
IKT News
- 2 months ago - Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - GlobeNewsWire
- 5 months ago - Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 9 months ago - Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 10 months ago - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewsWire